Proficio Capital Partners LLC Makes New $29.09 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

Proficio Capital Partners LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 148,040 shares of the medical research company’s stock, valued at approximately $29,091,000.

A number of other institutional investors have also added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new position in IQVIA in the third quarter worth $27,000. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at $33,000. Avior Wealth Management LLC increased its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of IQVIA during the third quarter valued at $57,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on IQV. Barclays reduced their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft dropped their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. UBS Group lowered their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, TD Cowen lowered their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Stock Performance

NYSE:IQV opened at $188.89 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $184.66 and a 1 year high of $261.73. The stock’s 50 day simple moving average is $199.13 and its two-hundred day simple moving average is $214.96. The company has a market cap of $33.26 billion, a price-to-earnings ratio of 25.19, a PEG ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.